Skip to content

Molecular regulatory mechanisms of gated attention regulation deficits in schizophrenia

Molecular regulatory mechanisms of gated attention regulation deficits in schizophrenia

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400085864
Enrollment
Unknown
Registered
2024-06-20
Start date
2024-06-20
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Health Control:None

Sponsors

Beijing Anding Hospital affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. 16-45 years old, right-handed, with a minimum of 6 years of education, and a Wechsler's intelligence score of over 70. 2. First episode schizophrenia: Meets the diagnostic criteria for schizophrenia in the American Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5); In the first episode of mental illness, with a course of less than 5 years, and no history of antipsychotic drug use. 3. Health control: matched with the age, gender, and education level of the patient group; No history of mental illness or family history. 4. The subjects and/or their guardians voluntarily sign an informed consent form and comply with the research protocol

Exclusion criteria

Exclusion criteria: Coarse lateral hearing abnormalities, previous major auditory system diseases; Women have a family planning plan during pregnancy or follow-up period; Serious neurological diseases (history of traumatic brain injury or infection, brain tumors, cerebrovascular diseases, epilepsy, etc.) or other physical diseases; Abnormalities with clinical significance in physical examination, laboratory indicators, electroencephalogram, and electrocardiogram; Have a history of alcohol and drug abuse or dependence within 6 months; Received electroconvulsive therapy or direct current/transcranial magnetic stimulation therapy within 6 months; High risk of suicide or impulsive behavior; Unable or unwilling to cooperate with effective evaluation.

Design outcomes

Primary

MeasureTime frame
Prepulse inhibition;

Secondary

MeasureTime frame
DNA methylation;Immune inflammation proteins;

Countries

China

Contacts

Public ContactMao Zhen

Beijing Anding Hospital affiliated to Capital Medical University

maozhen2015@126.com+86 10 5830 3129

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026